Free
Clinical Science  |   March 1999
Transdermal Nitroglycerine Enhances Spinal Sufentanil Postoperative Analgesia following Orthopedic Surgery 
Author Notes
  • (Lauretti, Mattos, Pereira) Assistant Professor.
  • (de Oliveira) Resident in Anesthesia.
  • (Reis) Associate Professor.
Article Information
Clinical Science
Clinical Science   |   March 1999
Transdermal Nitroglycerine Enhances Spinal Sufentanil Postoperative Analgesia following Orthopedic Surgery 
Anesthesiology 3 1999, Vol.90, 734-739. doi:
Anesthesiology 3 1999, Vol.90, 734-739. doi:
This article is featured in “This Month in Anesthesiology.” Please see this issue of Anesthesiology, page 7A.
SUFENTANIL is a potent analgesic used to manage perioperative pain associated with spinal block. The onset of analgesia is quicker than with morphine or fentanyl, but the duration of a single injection is shorter. [1] Thus, a continuous infusion or a combination of pharmacologically distinct analgesics is needed.
Previously we observed that patients with past histories of angina who had spinal block, in which the nitroglycerin transdermal patch (a nitric oxide [NO] generator [2]) was applied prophylactically, required fewer analgesics after operation. Data from the literature suggest that in humans, high-dose nitroglycerin patches, such as 30 mg daily, are hyperalgesic, [3] whereas doses less than 6 mg per day are analgesic under different circumstances. [4-6] The goal of this study was to determine whether a combination of transdermal nitroglycerine would enhance analgesia from a single intrathecal sufentanil administration in patients undergoing orthopedic surgery under intrathecal anesthesia. If clinically demonstrated, the combination of sufentanil and transdermal nitroglycerine would enhance postoperative analgesia while maintaining proper cardiac blood flow, which is already described in the literature. [7,8] 
Methods
The ethics committee of the University of Sao Paulo's Teaching Hospital, Ribeirao Preto, approved the study protocol. After giving informed consent, 56 patients classified as American Society of Anesthesiologists (ASA) physical status I and II and scheduled for minor orthopedic procedures (arthroscopy or meniscectomy) were randomized by computer to one of four groups and prospectively studied using a placebo-controlled, double-blinded design to examine analgesia and adverse effects. The number of patients was based on preliminary experimental data. We hypothesized that use of intrathecal sufentanil would increase the time to first rescue analgesic by 20% in the population studied, and that use of a transdermal nitroglycerin patch would increase the time to first rescue analgesic by 100% compared with the control group. If we estimated a 40% standard deviation for this prospective power analysis and an alpha value of 0.05, these assumptions would require five patients in each group to yield a 100% increase in the time to the first rescue analgesic. To increase further the power, we observed at least 12 patients in each group. A visual analog scale (VAS), which consisted of a 10-cm line with 0 equaling “no nausea”(VAS N) or “no pain at all” and 10 equaling “worst possible nausea” or “the worst possible pain” was introduced before surgery.
Patients were premedicated with 0.05 to 0.1 mg/kg intravenous midazolam in the holding room. Hydration consisted of 10 ml/kg lactate solution before operation and 10 ml [middle dot] kg-1[middle dot] h-1after spinal anesthesia. Spinal anesthesia was administered in the operating room at the L3-L4 interspace with the patient in the sitting position. A total volume of 5 ml was injected at 1 ml per 7 s through a 25-gauge spinal needle. The intrathecal drugs were 15 mg hyperbaric bupivacaine (3 ml) plus the test drug (2 ml). Patients were placed supine immediately after spinal injection. The transdermal patch was applied at the thorax, in a nonanesthetized area, 20 to 30 min after the spinal puncture (after hemodynamic stabilization). The drugs (intrathecal and transdermal) were prepared by one anesthesiologist. The second anesthesiologist who was blinded to the drug selection stayed during the operation and checked the patient after operation. Table 1describes the control group, sufentanil group, nitroglycerin group, and sufentanil-nitroglycerin group.
Table 1. Group Data
Image not available
Table 1. Group Data
×
Intraoperative sensory loss assessment included the pinprick test 5, 10, and 15 min after the injection. Blood pressure was monitored noninvasively every 5 min during surgery, and heart rate and oxyhemoglobin saturation were monitored continuously during surgery. A decrease in the mean arterial pressure more than 15% below the preanesthetic baseline level was treated by 4-mg incremental doses of ephedrine given intravenously. Decreases in heart rate to less than 50 beats/min were treated with 0.25-mg incremental doses of atropine given intravenously. Intraoperative nausea was scored by the patient using the 10-cm VAS N. The number of patients having nausea (of any degree) or vomiting at any point during operation was noted. Nausea greater than VAS 2/10 cm at any time or vomiting during the study were treated initially with 10 mg intravenous metoclopramide followed by 0.5 mg intravenous droperidol, if necessary. The VAS scores were averaged for patients with more than one episode of nausea.
Postoperative assessment included pain scores, adverse effects, and the duration of motor block, measured from anesthetic injection until the time a Bromage 2 score was achieved. [9] Patients were free to request rescue analgesics, and someone from the anesthesiology staff was always available to administer the analgesic when it was requested. Intramuscular diclofenac (75 mg) was available. Pain was assessed at the time of first rescue analgesic and 24 h after the spinal puncture by the anesthesiologist who was blinded to the treatment. Nausea and the occurrence of vomiting were assessed during operation and 24 h after the spinal puncture by the same anesthesiologist who was blinded to the treatment. The duration of effective analgesia was measured as the time from intrathecal drug administration to the patient's first request for analgesic administration in the recovery room or the infirmary, and it was recorded in minutes. The VAS at the time of first rescue analgesic medication was measured using the 10-cm VAS. The 24-h VAS pain score and VAS N reflected the patient's overall impression of the 24 h after spinal injection.
Statistical Analysis
The normality of the distributions was assessed using the Shapiro-Wilk test. Groups were compared for demographic data (age, weight, height) and duration of surgery by one-way analysis of variance. The incidence of adverse events, gender, ASA status, and adjuvant drug use were compared among the groups by chi-squared analysis corrected for multiple comparisons. P < 0.0125 was considered significant. Blood pressure, heart rate, level of anesthesia (pinprick), and VAS scores were compared among groups by two-way analysis of variance for repeated measures. [10] Tukey analysis was applied to decrease the probability of type 1 errors. The time to first rescue analgesics was compared using the Kruskal-Wallis test, which was applied along with a nonparametric multiple comparison procedure, the Wilcoxon rank sum test. The nonparametric tests, however, confirmed the findings of the parametric approach. P < 0.05 was considered significant. Data are expressed as the mean +/− SD unless otherwise stated.
Results
Fifty-five patients were evaluated. One patient from the control group was excluded from the final evaluation because the first spinal block failed. The four groups showed no differences regarding ASA status, gender, age, weight, and height (P > 0.05;Table 2). The level to pinprick at 5, 10, and 15 min, surgical and anesthetic time, and intraoperative ephedrine consumption were similar among groups (P > 0.05;Table 3). The mean blood pressure and pulse rate 5, 10, 15, 20, 30, and 40 min after the spinal injection were also the same in all groups (P > 0.05).
Table 2. Demographic Data
Image not available
Table 2. Demographic Data
×
Table 3. Intraoperative Data
Image not available
Table 3. Intraoperative Data
×
(Table 4) presents postoperative data. The pain VAS score at the time of first rescue analgesic medication was similar among the four groups (P = 0.1120). The time to first rescue analgesic medication was longer for the sufentanil-nitroglycerin group compared with all other groups (P < 0.005), and it was longer for the sufentanil group compared with the control group (P < 0.05). Figure 1describes the data plots for each patient. The number of intramuscular diclofenac dose injections in 24 h was smaller for the sufentanil-nitroglycerin group compared with all other groups (P < 0.02). The sufentanil-nitroglycerin group 24-h pain VAS scores were lesser compared with the control group (P = 0.0026) but similar to the other groups (sufentanil group and nitroglycerin group)(P > 0.05).
Table 4. Postoperative Data
Image not available
Table 4. Postoperative Data
×
Figure 1. A normal dot plot for each patient. [black circle] Mean +/− SD. CG = control group, SG = sufentanil group, NG = nitroglycerine group, SNG = sufentanil-nitroglycerine group. P values for the Shapiro-Wilk test: CG, P < 0.0376; SG, P < 0.0055; NG, P < 0.0435; SNG, P < 0.0018.
Figure 1. A normal dot plot for each patient. [black circle] Mean +/− SD. CG = control group, SG = sufentanil group, NG = nitroglycerine group, SNG = sufentanil-nitroglycerine group. P values for the Shapiro-Wilk test: CG, P < 0.0376; SG, P < 0.0055; NG, P < 0.0435; SNG, P < 0.0018.
Figure 1. A normal dot plot for each patient. [black circle] Mean +/− SD. CG = control group, SG = sufentanil group, NG = nitroglycerine group, SNG = sufentanil-nitroglycerine group. P values for the Shapiro-Wilk test: CG, P < 0.0376; SG, P < 0.0055; NG, P < 0.0435; SNG, P < 0.0018.
×
There were no differences regarding the incidence of perioperative adverse effects (P > 0.05). During operation, none of the patients reported nausea or vomiting. One patient from the sufentanil-nitroglycerin group had bradycardia (43 beats/min) and hypotension 30 min after the spinal puncture, coincident in time with the transdermal patch application. The patient was treated successfully with intravenous ephedrine. Three patients from the sufentanil group and two from the sufentanilnitroglycerin group reported perioperative pruritus of their hands, nose, and thorax. One patient each from the sufentanil and the nitroglycerin groups reported postoperative headache (VAS 5 and 6, respectively). One patient from the sufentanil group had urinary retention. Finally, one patient from the sufentanil-nitroglycerin group reported postoperative lumbar pain (VAS 6), and another reported postoperative epigastralgia (VAS 2), nausea (VAS 4), and headache (VAS 6). The mean overall 24-h nausea VAS scores were control group (0.5 +/− 1)= sufentanil group (0.4 +/− 1.5)= nitroglycerin group (0.5 +/− 1)= sufentanil-nitroglycerin group (0.7 +/− 1.6)(P = 0.9999).
Discussion
The results indicate that 10 [micro sign]g intrathecal sufentanil resulted in 5.4 h of analgesia after the spinal puncture, or 3 h from the end of the spinal block, but resulted in the same analgesic postoperative consumption compared with the control group, in accordance with findings reported in the literature. Spinal sufentanil, compared with morphine, has been shown to produce a faster and more intense analgesia but of shorter duration. Patients requested additional analgesics within 3 h of the end of the anesthesia, and their morphine consumption during the first 24 h after surgery was similar to that found after general anesthesia. [11] A dose-response curve for intrathecal sufentanil during labor suggested that the median effective dose (ED50) for intrathecal sufentanil was 2.5 [micro sign]g and that the ED95between 7.5 and 10 [micro sign]g. [11] 
Our results also showed that 5 mg transdermal nitroglycerine alone did not result in postoperative analgesia, but a 5-mg transdermal nitroglycerin patch enhanced the sufentanil analgesic effect. Their combination resulted in 13 h of postoperative analgesia after arthroscopy and meniscectomy. Nitric oxide has been shown to interact synergistically with morphine after intravenous or spinal administration. [12] Recent animal studies showed that peripherally administered NO had no analgesic effect, but it enhanced the analgesic effect of peripherally administered morphine during experimental inflammation in rats. [13] In addition, systemic morphine increased spinal cord NO metabolite concentrations, and behavioral analgesia in healthy animals from systemic morphine is blocked by NO synthase inhibitors. [14] How NO would enhance sufentanil analgesia is not known, and at least four explanations are possible: a supraspinal, spinal, or peripheral mechanism, or molecular pharmacology.
Nitric oxide derived from transdermal nitroglycerine may enhance the antinociceptive effect produced by intrathecal sufentanil through the supraspinal mechanism. Intrathecal injection of L-arginine and NO-releasing compounds produced hyperalgesia in the tail-flick test, [15] formalin pain model, [16] and neuropathic pain model. [17] In contrast, intracerebroventricular administration of L-arginine or dibutyril cyclic guanosine monophosphate (cGMP) produced antinociception via the NO-cGMP pathway in the tail-flick procedure. [18-20] According to the data described, NO exerts a dual role in acute nociceptive processing. Intrathecal NO plays a role in thermal hyperalgesia, whereas intracerebroventricular NO plays a role in thermal antinociception.
Conversely, NO derived from transdermal nitroglycerine may enhance the antinociceptive effect produced by intrathecal sufentanil through the spinal mechanism. The analgesic effect after opioid administration is mediated in part through activation of inhibitory descending pain pathways that will involve the participation of NO, which mechanisms of action are likely to include activation of second messengers such as cGMP. [21] Spinal activation of the NO-cGMP signal transduction system contributes to sensitization of wide dynamic range neurons located in the deep dorsal horn. In contrast, wide dynamic range neurons in the superficial dorsal horn and high-threshold cells in the superficial or deep layers show a reduced response after exposure to cGMP. [22] Thus, No may exert a dual role in acute nociceptive processing. The analgesia would be a result of a predominant analgesic action on superficial spinal layers, and thus the nociceptive effect would be a result of a predominant action on deep layers.
Peripherally, NO produces neither nociceptive nor antinociceptive effects on the receptors. [23] However, it modulates the antiinflammatory process and edema formation. Its vasodilator action on the venous system decreases the vasoconstrictor tone induced by the inflammatory process and further reduces the edema formation. [4] Nitric oxide also produces platelet desegregation, impeding the platelet adhesion to the endothelium of the injured vessel. [24] In addition, NO generators induce antiinflammatory effects and analgesia by blocking hyperalgesia and the neurogenic component of the inflammatory edema. [25] Another possible mechanism includes an analgesic effect through the direct stimulation of peripheral fibers mimicking the actions of locally applied acetylcholine. [26] 
Finally, the molecular pharmacology modulation also may be proposed for the mechanism of synergistic interaction between [micro sign]-opioid receptors and NO. Nitric oxide may act directly at the [micro sign]-opioid receptor for the positive modulation and enhance its function. Nitric oxide has been reported to have direct modulatory effects on N-methyl-D-aspartate receptors [27] and gamma-aminobutyric acid-A receptors. [28] However, the molecular nature of the action of NO at the [micro sign]-opioid receptor has not been clarified.
In conclusion, although transdermal nitroglycerine alone (5 mg/day), an NO generator, did not result in effective postoperative analgesia, its association with intrathecal sufentanil provided 13 h of postoperative analgesia after minor knee surgery, suggesting that NO and [micro sign]-opioid receptors may enhance their antinociceptive effects on the dose studied. Whether this represents a synergistic action or some other mechanism could not be determined from these data.
The authors thank Professor William Alves do Prado of the Department of Pharmacology-FMRP-USP for his advice concerning spinal mechanisms, and Professor Cleber A. J. Paccola of the Department of Surgery, Orthopedics, and Traumatology of the FMRP-USP, who was the surgeon responsible for the patients.
REFERENCES
Rostaing S, Bonnet F, Levron JC, Vodinh J, Pluskwa F, Saada M: Pharmacokinetics of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. Anesthesiology 1991; 75:42-5
Feelisch M, Noack EA: Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139:19-30
Koerig HM, Chowdhury P: A comparison of the effects of nitroglycerine ointment, EMLA cream and zinc oxide on the degree of pain associated with pin prick. Anesth Analg 1996; 82:240
Berrazueta JR, Fleitas M, Salas E, Amado JA, Poveda JJ, Ochoteco A, Sanchez de Veja MJ, Ruiz de Celis G: Local transdermal glyceryl trinitrate has an antiinflammatory action on thrombophlebitis induced by sclerosis of leg varicose veins. Angiology 1994; 45:347-51
Pittrof R, Lees C, Thompson C, Pickles A, Martin JF, Campbell S: Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea. BMJ 1996; 312:884
Lauretti GR, Lima ICPR, Gomes JMS, Reis MP: Nitroglycerin Polymer and oral ketamine as adjuvants in the chronic cancer pain therapy. Reg Anesth 1997; 22:71
Matheis G, Sherman MP, Buckbeerg GD, Haybron DM, Young HH, Ignarre LJ: The role of L-arginine nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol 1992; 262:616-20
Schroeder RA, Kuo P: Nitric oxide: Physiology and pharmacology. Anesth Analg 1995; 81:1052-9
Bromage PR: A comparison of the hydrochloride salts of lidocaine and prilocaine in epidural analgesia. Acta Anesthesiol Scand 1965; 16:55-9
Dexter F, Chestnut DH: Analysis of statistical tests to compare visual analog scale measurements among groups. Anesthesiology 1995; 82:896-902
Celleno D: Spinal sufentanil. Anaesthesia 1998; 53:49-50
Yamagushi H, Naito H: Antinociceptive synergistic interaction between morphine and n sup [small omega, Greek]-nitro 1-arginine methyl; Esther on thermal nociceptive tests in the rats. Can J Anaesth 1996; 43:975-81
Nozaki-Taguchi N, Yamamoto T: The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation. Anesth Analg 1998; 86:367-73
Bouaziz H, Tong CY, Yoon Y, Hood DD, Eisenach JC: Intravenous opioids stimulate norepinephrine and acetylcholine release in spinal cord dorsal hors-Systematic studies in sheep and an observation in a human. Anesthesiology 1996; 84:143-54
Meller ST, Dykstra C, Gebhart GF: Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-flick reflex. Eur J Pharmacol 1992; 214:93-6
Kitto KF, Haley JE, Wilcox GL: Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci Lett 1992; 148:1-5
Inoue T, Mashimo T, Shibata M, Shibuta S, Yoshiya I: Rapid development of nitric oxide-induced hyperalgesia depends on na alternate to the cGMP-mediated pathway in the rat neuropathic pain model. Brain Res 1998; 792:263-70
Vocci FJ, Petty SK, Dewey WL: Antinociceptive action of the butyryl derivatives of cyclic guanosine 3:5-monophosphate. Pharmacol Exp Ther 1978; 207:892-8
Tseng LF, Xu JY, Pieper GM: Increase of nitric oxide production by L-arginine potentiates i.c.v. administered beta-endorphin-induced antinociception in the mouse. Eur J Pharmacol 1992; 211:301-3
Kawabata A, Umeda N, Takagi H: L-arginine exerts a dual role in nociceptive processing in the brain: Involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway. Br J Pharmacol 1993; 109:73-9
Zhuo M, Meller ST, Gebhart GF: Endogenous nitric oxide is required for tonic cholinergic inhibition of spinal mechanical transmission. Pain 1993; 54:71-8
Lin Q, Peng YB, Wu J, Willis WD: Involvement of cGMP in nociceptive processing by and sensitization of spinothalamic neurons in primates. J Neurosci 1997; 17:3293-302
Mashimo T, Pak M, Choe H, Inagaki Y, Yamamoto M, Yoshiya I: Effects of vasolidators guanethidine, nicardine, nicardine, nitroglycerin, and prostaglandin E1 on primary afferent nociceptors in human. J Clin Pharmacol 1997; 37:330-5
Berenger FP, Friggi A, Bodard H, Rolland PH: Control of the anti-thrombogenic endothelial cell defense by short- and long-term exposure of culture endothelial cells to isosorbide nitrates. Eur Heart J 1998; 9:3-9
Ferreira SH, Lorenzetti BB, Faccioli LH: Blockade of hyperalgesia and neurogenic oedema by topical application of nitroglycerin. Eur J Pharmacol 1992; 217:207-9
Duarte IDC, Lorenzetti BB, Ferreira SH: Acetylcholine induces peripheral analgesia by the release of nitric oxide, Nitric Oxide from L-Argenine. A Bioregulatory System. Edited by S Moncada, EA Higgs. Amsterdam, Elsevier, 1990, pp 165-70
Bogdanov MB, Wurtman RJ: Possible involvement of nitric oxide in NMDA-induced glutamate release in the rat striatum: An in vivo microdialysis study. Neurosci Lett 1997; 221:197-201
Fukami S, Uchida I, Mashimo T, Takenoshita M, Yoshiya I: Gamma subunit dependent modulation by nitric oxide (NO) in recombinant GABA-A receptor. Neuroreport 1998; 20:1089-92
Figure 1. A normal dot plot for each patient. [black circle] Mean +/− SD. CG = control group, SG = sufentanil group, NG = nitroglycerine group, SNG = sufentanil-nitroglycerine group. P values for the Shapiro-Wilk test: CG, P < 0.0376; SG, P < 0.0055; NG, P < 0.0435; SNG, P < 0.0018.
Figure 1. A normal dot plot for each patient. [black circle] Mean +/− SD. CG = control group, SG = sufentanil group, NG = nitroglycerine group, SNG = sufentanil-nitroglycerine group. P values for the Shapiro-Wilk test: CG, P < 0.0376; SG, P < 0.0055; NG, P < 0.0435; SNG, P < 0.0018.
Figure 1. A normal dot plot for each patient. [black circle] Mean +/− SD. CG = control group, SG = sufentanil group, NG = nitroglycerine group, SNG = sufentanil-nitroglycerine group. P values for the Shapiro-Wilk test: CG, P < 0.0376; SG, P < 0.0055; NG, P < 0.0435; SNG, P < 0.0018.
×
Table 1. Group Data
Image not available
Table 1. Group Data
×
Table 2. Demographic Data
Image not available
Table 2. Demographic Data
×
Table 3. Intraoperative Data
Image not available
Table 3. Intraoperative Data
×
Table 4. Postoperative Data
Image not available
Table 4. Postoperative Data
×